Skip to main content
. 2009 Jan 20;100(3):476–486. doi: 10.1038/sj.bjc.6604873

Figure 5.

Figure 5

Dual tumour MCF-7wt and MCF-7.MR xenograft model. Female MF-1 nu/nu mice were injected s.c. in one flank with 5 × 106 MCF-7wt cells and in the other with 5 × 106 MCF-7.MR cells in ice-cold Matrigel (n=6 per group). Daily oral administration of STX140 vehicle (0.1 ml 10% THF/90% propylene glycol), STX140 (20 mg kg−1), or twice weekly i.v. administration of MXR (1.0 and 2.5 mg kg−1 in saline) was initiated when the tumours reached 50–150 mm3 in volume (day 0). (A) MCF-7wt tumour growth: dosing with STX140 or either dose of MXR caused significant inhibition of tumour growth (***P<0.001 and *P<0.05, respectively) compared to control. (B) MCF-7.MR tumour growth: dosing with STX140 caused significant inhibition of tumour growth (***P<0.001) compared to control, whereas dosing with MXR at either dose did not affect tumour growth (ns, P>0.05). (C) BCRP mRNA expression: RT–PCR analysis, using Taqman expression assays for BCRP, and for an endogenous control gene, RPLO, of mRNA extracted from MCF-7wt and MCF-7.MR tumours at the end of the study.